1259917-08-2Relevant academic research and scientific papers
Favorskii-like rearrangement of an aliphatic α-halo amide
Kelly, Nicholas M.,Wellejus, Anja,Elbrond-Bek, Heidi,Weidner, Morten Sloth,Jorgensen, Signe Humle
supporting information, p. 1243 - 1249 (2013/04/10)
The reaction of the α-bromoamide 2a with 1-cyclopentylpiperazine gives the Favorskii-like rearranged product 4 when the reaction is heated to 70 °C in a mixture of aqueous potassium hydroxide and ethanol. However, when solid sodium carbonate/potassium iodide is used in ethanol, the nonrearranged product 3a is formed instead. Supplemental materials are available for this article. Go to the publisher's online edition of Synthetic Communications to view the free supplemental file.
Synthesis and biological evaluation of Esaprazole analogues showing σ1 binding and neuroprotective properties in vitro
Kelly, Nicholas M.,Wellejus, Anja,Elbr?nd-Bek, Heidi,Weidner, Morten Sloth,J?rgensen, Signe Humle
, p. 3334 - 3347 (2013/07/11)
Esaprazole, a molecule previously acknowledged to protect against stomach and intestinal ulcers was surprisingly discovered to have neuroprotective activities and σ1 binding in vitro. A highly diverse set of Esaprazole analogues 2-5 was prepared in order to increase blood-brain barrier penetration. The analogues showed a structure-activity relationship at the σ1 receptor closely matching already published pharmacophores. Many of the analogues were shown to have neuroprotective properties in two assays using primary cultures of cortical neurons exposed to glutamate and hydrogen peroxide. However, no apparent SAR for these two assays could be developed. Metabolic stability of the analogues were also investigated and the structure of R1 had a significant bearing on the ADME properties of the compound resulting in two series of compounds. Compounds in which R 1 was a H or acyl group had good metabolic stability in RLM but poor BBB penetration, whereas compounds where R1 was a cyclo- or bicyclo-alkyl group had poor metabolic stability but good BBB penetration.
AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS
-
Page/Page column 60, (2011/02/24)
An aminoalkarnide of the formula I for use as a medicament to treat inflammatory, degenerative or demyelinating diseases of the CNS in a subject in need thereof.
